|Bid||645.09 x 1200|
|Ask||646.11 x 1100|
|Day's range||643.29 - 651.93|
|52-week range||441.00 - 686.62|
|Beta (5Y monthly)||0.16|
|PE ratio (TTM)||11.65|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||677.04|
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.
Let's take a close look at the area smart investors are watching right now. The U.S. Food and Drug Administration has authorized such treatments by Regeneron (NASDAQ: REGN), Eli Lilly (NYSE: LLY), and Vir Biotechnology (NASDAQ: VIR).